Cagrilintide/semaglutide - Novo Nordisk
Alternative Names: CagriSema; NN-9388Latest Information Update: 23 Jul 2024
At a glance
- Originator Novo Nordisk
- Class Antihyperglycaemics; Glucagon-like peptides; Hepatoprotectants; Obesity therapies; Urologics; Vascular disorder therapies
- Mechanism of Action Amylin receptor agonists; Fibroblast growth factor receptor agonists; Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Obesity; Type 2 diabetes mellitus
- Phase II Renal failure
- Phase Unknown Substance-related disorders
Most Recent Events
- 24 Jun 2024 Novo Nordisk initiates a phase III trial for Obesity in United Kingdom, USA and Canada (SC) (NCT06388187)
- 07 Jun 2024 Investigation in Substance-related disorders (Combination therapy) in USA, Australia (SC) (NCT06409130)
- 06 May 2024 Novo Nordisk initiates a phase I trial for Type diabetes mellitus in Germany (SC) (NCT06403761) (EudraCT-2023-509483-20)